TriStar Centennial Medical Center

Dr. Andrew S. Kennedy

Claim this profile

Henrico Doctor's Hospital

Studies Breast Cancer
Studies Prostate Adenocarcinoma
7 reported clinical trials
28 drugs studied

Area of expertise

1

Breast Cancer

Andrew S. Kennedy has run 2 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage II
2

Prostate Adenocarcinoma

Andrew S. Kennedy has run 1 trial for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.

Henrico Doctors Hospital

Image of trial facility.

Mission Hospital

Clinical Trials Andrew S. Kennedy is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

More about Andrew S. Kennedy

Clinical Trial Related

3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Andrew S. Kennedy has experience with

  • Radiation
  • Tamoxifen
  • Anastrozol
  • Letrozole
  • Exemestane
  • Relugolix

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Andrew S. Kennedy specialize in?

Is Andrew S. Kennedy currently recruiting for clinical trials?

Are there any treatments that Andrew S. Kennedy has studied deeply?

What is the best way to schedule an appointment with Andrew S. Kennedy?

What is the office address of Andrew S. Kennedy?

Is there any support for travel costs?